0000947871-22-000475.txt : 20220422 0000947871-22-000475.hdr.sgml : 20220422 20220422163359 ACCESSION NUMBER: 0000947871-22-000475 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220421 FILED AS OF DATE: 20220422 DATE AS OF CHANGE: 20220422 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BioLexis Pte Ltd. CENTRAL INDEX KEY: 0001716335 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37759 FILM NUMBER: 22846034 BUSINESS ADDRESS: STREET 1: 36 ROBINSON ROAD, #13-01 CITY HOUSE CITY: SINGAPORE STATE: U0 ZIP: 068877 BUSINESS PHONE: 962 6 582 7999 MAIL ADDRESS: STREET 1: 36 ROBINSON ROAD, #13-01 CITY HOUSE CITY: SINGAPORE STATE: U0 ZIP: 068877 FORMER NAME: FORMER CONFORMED NAME: GMS Tenshi Holdings Pte. Ltd DATE OF NAME CHANGE: 20170906 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Outlook Therapeutics, Inc. CENTRAL INDEX KEY: 0001649989 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 383982704 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 BUSINESS PHONE: 6096193990 MAIL ADDRESS: STREET 1: 485 ROUTE 1 SOUTH STREET 2: BUILDING F, SUITE 320 CITY: ISELIN STATE: NJ ZIP: 08830 FORMER COMPANY: FORMER CONFORMED NAME: Oncobiologics, Inc. DATE OF NAME CHANGE: 20150804 4 1 ownership.xml X0306 4 2022-04-21 0 0001649989 Outlook Therapeutics, Inc. OTLK 0001716335 BioLexis Pte Ltd. 36 ROBINSON ROAD, #13-06 CITY HOUSE P.O. BOX 142904 SINGAPORE U0 068877 SINGAPORE 0 0 1 0 Common Stock 2022-04-21 4 J 0 27982529 D 22982529 D On April 21, 2022, the Reporting Person entered into a share purchase agreement with GMS Ventures & Investments ("GMS Ventures") pursuant to which, in connection with the transactions contemplated thereby (the "Restructuring"), GMS Ventures took direct ownership of the Issuer's shares that GMS Ventures and its affiliates (collectively, "GMS") indirectly held through its ownership in the Reporting Person. The transfer of the Issuer's shares to GMS Ventures in connection with the Restructuring occurred at the historic cost basis of GMS's investment in the Reporting Person for accounting purposes. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the price at which the transfer was effected. GMS does not have an economic interest in, or voting rights with respect to, the shares of the Issuer held by the Reporting Person. Following the completion of the Restructuring, Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), will become the sole shareholder of the Reporting Person. Kumar, a natural person, is the holder of a controlling interest in Tenshi. By virtue of these relationships, Kumar may be deemed to have voting and investment power with respect to the securities held by the Reporting Person and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. In connection with the Restructuring, the Reporting Person intends to change its name to "Tenshi Healthcare Partners". /s/ BioLexis Pte. Ltd., By: Lawrence Kenyon, Attorney-in-Fact 2022-04-22